Sony SD Cards Are Over Half Off on Amazon Right Now
You can always use more memory cards. Whether you're a weekend warrior with your DSLR or a music hoarder on your smartphone, these bite-size bits of storage tend to fill up quickly, and they're easy to lose at that. So take the chance while you've got it, and stock up on Sony memory cards at Amazon. They're mad cheap today.
FILE - In this July 26, 2013, file photo, Sean "Diddy" Combs of Revolt TV waits to take the stage for a news conference about the new channel during the Television Critics Association summer press tour at the Beverly Hilton Hotel, in Beverly Hills, Calif. Already a success in music and fashion, Combs has big dreams for television, too, wanting to build a network that will be seen as the ESPN of music. (Photo by Chris Pizzello/Invision/AP, File)
FILE - In this July 26, 2013, file photo, Sean "Diddy" Combs of Revolt TV waits to take the stage for a news conference about the new channel during the Television Critics Association summer press tour at the Beverly Hilton Hotel, in Beverly Hills, Calif. Already a success in music and fashion, Combs has big dreams for television, too, wanting to build a network that will be seen as the ESPN of music. (Photo by Chris Pizzello/Invision/AP, File)
FILE - In this July 26, 2013, file photo, Sean "Diddy" Combs of Revolt TV waits to take the stage for a news conference about the new channel during the Television Critics Association summer press tour at the Beverly Hilton Hotel, in Beverly Hills, Calif. It was fitting that the rap impresario Combs opened his new Revolt TV music channel Monday, Oct. 21, 2013, on the steps of the Notorious B.I.G.'s old home, introducing a video for the late artist's 1994 song, "Juicy." (Photo by Chris Pizzello/Invision/AP, File)
NEW YORK (AP) — Sean Combs' new Revolt channel launched with a nod to big dreams and its founder's musical past, bringing a new outlet for music to television.
Despite some technical glitches in its opening Monday, Combs aspires to nothing less than making Revolt the ESPN of music, with well-curated playlists and a strong focus on industry news.
"I want to know, who is Taylor Swift?" Combs said. "Why is Miley Cyrus twerking? Why did Jay-Z and Justin Timberlake go on tour? Why did Kanye West call his daughter 'North'? The industry of music is just as important, or more important, as the industry of sports. Sports are covered in a serious manner and we want to follow in those footsteps."
Most fans watch videos online or on demand these days, despite the existence of MTV's networks, Fuse and BET. The struggling music industry doesn't spend as much producing flashy videos as it did in MTV's heyday. Networks that have started out primarily with videos moved on, primarily because the format is unattractive to advertisers.
"We're just going to do it better," said Val Boreland, Revolt's chief programming executive. Combs said he wants a network where people program from the gut instead of sales charts, citing legendary DJ Frankie Crocker and "Soul Train." His executive team is heavy on industry experience, with former ESPN executive and Vibe magazine president Keith Clinkscales, former Warner Bros. and MTV executive Andy Schuon and Boreland, who worked at Comedy Central.
Boreland said Revolt will stay in contact with viewers through social media and said Fuse, for example, does not have a strong connection with fans. A Fuse spokeswoman declined to make an executive available to talk about Revolt, or the difficulties of beginning a new network.
At its start, Revolt is available only on Time Warner and some Comcast cable outlets. The channel's website is live streaming the first three days. Combs is encouraging fans to contact cable and satellite operators to urge them to begin airing Revolt.
Monday night's online launch was marred by technical problems that operators blamed on demand. The picture repeatedly froze as Combs talked from the front steps of a Brooklyn home where the late Notorious B.I.G. grew up. The opening video was Biggie's 1994 song "Juicy," a song Combs produced in his Puff Daddy days, where the artist looked back on an improbable journey that began with big ambitions.
From there, Combs and former MTV VJ LaLa Anthony played tracks from the French DJ and producer Gesaffelstein, the California hip-hop duo Audio Push and the British electronic music duo Disclosure.
Revolt will air videos almost exclusively with a few news reports sprinkled in until January, when a new studio in Los Angeles opens for artist interviews and concerts.
Combs was compelled to release a video a few weeks ago making clear that Revolt will cover all forms of music. One of its two announced shows will focus exclusively on rock.
"People have made an assumption, because I'm a hip-hop artist and I'm African-American, that I'm going to try to make a second version of BET," Combs said, "which I'm not."
He said he's wanted to start a music channel for several years, and looked into acquiring a struggling network and changing its format. His dreams meshed with Comcast, which was seeking networks with minority ownership.
At a party a few weeks ago, Combs ran into Oprah Winfrey and asked if she recognized his look of a stressed-out entrepreneur. Winfrey, whose own network got off to a rocky start, advised him to stay tough.
"It's the hardest thing I've ever done," Combs said, "and it's the most exciting thing I've done in a long time."
___
Online:
www.revolt.tv
___
EDITOR'S NOTE — David Bauder can be reached at dbauder@ap.org or on Twitter@dbauder. His work can be found at http://bigstory.ap.org/content/david-bauder.
With $2.6M From SoftTech, 500 Startups & More, BetterDoctor Wants To Take The Pain Out Of Finding The Best Local Care
After a frustrating search to find the best local doctor in San Francisco during a “series of family emergencies,” Ari Tulla teamed up with friend and co-founder Tapio Tolvanen to do something about it. The result of what Tulla calls his “vendetta against the broken healthcare system” is BetterDoctor, a search engine and ranking service for doctors, which launched in September.
As veterans of the mobile space, most recently at Nokia, the co-founders focused on building a simple, device-friendly interface around their physician database, starting with an iPhone app and a mobile-optimized web experience for iOS and Android. Since launching in September, the search engine has grown from 5,000 doctors in 5 medical specialties to over 1 million across 60 medical specialties. Today, the co-founders tell us, over four million people have used the service to find a doctor, and 5,000 physicians have now signed up to access its “doctor dashboard.”
With one million people now using BetterDoctor to search for local physicians each month and with a staff that’s grown to 21, the startup is looking to expand and to refine its matchmaking algorithms. To do so, the startup is taking on $2.6 million in seed funding from Jeff Clavier at SoftTechVC, 500 Startups and Burrill & Co. As a result of the round, Clavier and Burrill & Co.’s Dirk Lammerts will be joining BetterDoctor’s board of directors.
Of course, part of the work that lies ahead, which the new funding aims to assist, is raising the level of awareness for BetterDoctor among physicians. While one million doctors are listen on the service — and 300,000 have passed the startup’s “quality screening,” which means their experience, education, licenses, board certifications and referral network all fit the bill — many of these doctors are unfamiliar with the service.
While some physicians are wary of listing services, as it can be difficult to tell which are legitimate, which will stand the test of time and which can actually add value, BetterDoctor hopes to get over the hump by acting as a lead-generation service. Some physicians have over 10,000 profile views on BetterDoctor, Tulla says, and as a result, the company is looking to help doctors not only find more patients but market their practice more effectively.
Physicians who sign up and pay to use the service — become “verified” — can claim their profile and use BetterDoctor to promote themselves and their practice. However, to avoid skewing search results, the service takes into account both consumer and peer feedback, as well as qualifications, to avoid surfacing only those “doctors who pay the most, but might not be of good quality,” Tulla says.
That’s how the co-founders believe that the service can compete with ZocDoc and now Practice Fusion (among others), which offer ways for consumers to search, browse recommendations and book appointments online.
Furthermore, because 90 percent of people still book doctor appointments by phone, Tulla believes that by creating a mobile-friendly and focusing on simplicity, it can offer users a better search experience. The other area where BetterDoctor can create an advantage is by focusing on matchmaking and connecting patients with the right doctor.
Combining both of these factors, when using the service on the mobile web, users can search by specialty on the majority of mobile devices, improving recommendations by keying in your insurance plan. The service is also, thankfully, devoid of advertisements and does not list doctors with negative ratings or those who have had legal trouble or are fighting malpractice suits.
The team isn’t ready to go into details on its new plans for improving rankings and matchmaking, but it’s clear that this is where it will focus most of its attention going forward. If BetterDoctor can convince more doctors to claim their profiles and sign on, offer more information about their services and information coverage, and if it can hone its patient-doctor matchmaking, the startup could help make the tedious process of searching for doctors that much better.
Public Support For Marijuana Legalization Hits Record High
An ATM sits next to a rack of marijuana clone plants that are used to grow medical marijuana on Wednesday at The Joint, a medical marijuana cooperative in Seattle. Last week Washington became the second U.S. state to adopt rules for the recreational sale of marijuana.
Ted S. Warren/AP
An ATM sits next to a rack of marijuana clone plants that are used to grow medical marijuana on Wednesday at The Joint, a medical marijuana cooperative in Seattle. Last week Washington became the second U.S. state to adopt rules for the recreational sale of marijuana.
Ted S. Warren/AP
A record number of Americans are in favor of legalizing marijuana, according to a new Gallup poll released Tuesday.
The poll, which was conducted Oct. 3-6, reports that 58 percent of the public supports the legalization of marijuana, while 39 percent opposes it.
The tide of public opinion appears to be rapidly turning in favor of legalization. In November 2012, Gallup found that 48 percent of Americans favored marijuana legalization compared with 50 percent who did not. Just over a decade earlier, in 2001, only 31 percent supported legalization while 64 percent opposed it.
The first time Gallup recorded a majority of Americans in favor of legalization came in 2011, when 50 percent said they supported it and 46 percent said they opposed it.
The issue remains a fairly partisan one: Sixty-five percent of Democrats support legalizing marijuana, compared with 35 percent of Republicans. Meanwhile, 62 percent of independents say they are pro-legalization, up from 50 percent last year.
Every age group Gallup tested was in favor of marijuana legalization except for those 65 and older. Fifty-three percent of respondents in that group said they were against legalization, while 45 percent were in support.
Americans between the ages of 18 and 29 are still the most likely to back legalizing marijuana. Of that age group, two-thirds — 67 percent — favor legalization while 31 percent would like to see the drug remain illegal.
The results follow some major victories for pro-legalization forces. Colorado and Washington became the first states to legalize the recreational use of marijuana last year, and the Justice Department announced in August it would not challenge the laws.
Advocates are also moving forward with efforts to put a marijuana legalization referendum on the ballot in 10 other states over the next four years.
Nobody gives good sneer like Tom Hiddleston, back once again in the pleather leggings and goat-horned helmet to play bad guy Loki in Thor: The Dark World and pretty much steal the whole show. Amiable hunk Chris Hemsworth may play the title character in this subset of Marvel's meta-Avengers franchise, but this well-intentioned "witless oaf," as his evil foster brother describes him at one point, is practically a guest at his own party here, as scads of new characters and millions of dollars worth of CGI crowd the screen. Most of it pales into insignificance when Loki takes the stage, which isn't often enough given how wildly uneven the sections without him are. Although director Alan Taylor manages to get things going properly for the final battle in London, the long stretches before that on Asgard and the other branches of Yggdrasil are a drag, like filler episodes of Game of Thrones but without the narrative complexity, mythical heft or all-pervading sexiness.
In a year when so many box-office sure bets, especially sequels, have been a bust, it's harder than usual to predict how well Thor: The Dark World will do. Tracking numbers are predicting an opening weekend somewhere in the $75 million stratosphere. Meh word of mouth could diminish returns over the subsequent weeks, but who knows. There are a lot of die-hard fans out there, especially for the Marvel-verse, but then again they can also be a very discerning and exacting audience.
The opening sequence provides backstory on the Dark Elves, sharp-beaked, pointy-eared meanies from Alfheim who date back to before the beginning of time and claim a black, gaseous substance called Aether as their all-powerful weapon of mass destruction. They're seen being vanquished (but, of course, not quite) by Thor's grandfather. Thereafter, the story basically picks up where TheAvengers left off, with Loki in manacles back on Thor's home planet -- or "realm," they call it -- Asgard, after trying to take over our world and trashing New York in the process. His glass-walled, whited-out cell in the dungeon bears a striking resemblance to similar baddie-holding pens in films past, from the X-Men franchise to Skyfall; there he reads books and has heart-to-black-heart chats with his adopted mother, Frigga (Rene Russo, finally getting more to do in this installment than just standing around smiling).
In uppity other realms, Thor has been putting down insurgents alongside his warrior buddies -- the Lady Sif (Jaimie Alexander), and the "Warriors Three," Volstagg (Ray Stevenson), Hogun (Tadanobu Asano) and Fandral (Zachary Levi, stepping in for Josh Dallas) -- and preparing to take over from dad Odin (Anthony Hopkins) as king. Since the Bifrost bridge that connects Asgard to Earth was destroyed two films back, Thor has no means to travel to our world to see Jane Foster (Natalie Portman), the fetching lady scientist he became smitten with in the first movie but barely mentioned in The Avengers.
Luckily, omnipotent bridge-keeper Heimdall (Idris Elba) can see she's basically fine, albeit mightily annoyed with Thor for not staying in touch. Based in London now, she's trying to heal her wounded pride by having a blind date with nice but decidedly non-godly Richard (Chris O'Dowd, criminally underused). She dumps him unceremoniously as soon as her intern Darcy (Kat Dennings), who now has her own intern (Jonathan Howard), interrupts their meal with evidence of a space-fabric disturbance that seems familiar. While investigating the weird phenomenon, Darcy is sucked into another realm and infected with Aether, which sometimes give her scary white-free eyes, evoking happy memories of Black Swan.
It turns out that The Convergence, the incredibly rare astronomical alignment of all nine realms, is beginning, hence the possibility of Bifrost-free travel between Earth and Asgard. Thor comes to collect Jane, gets slapped a few times for not calling her, and they commute back to Asgard to see its intricate landscape of cavernous assembly halls and gleaming golden towers, fashioned in the forge of many a mainframe, all impressively conceived and executed by production designer Charles Wood and visual effects supervisor Jake Morrison. That said, some of the more barren landscapes look decidedly less convincing with their papier-mache boulders and screen-like backdrops when Malekith (Christopher Eccleston), the leader of the surviving Dark Elves and his crew, come to try and collect their Aether.
The middle section is mostly a muddle, with endless cross-cutting between the Dark Elves plotting, attacking and then retreating to plot some more, earthlings Darcy and Dr. Erik Selvig (Stellan Skarsgard) worrying, and the Asgardians bickering over what they should do. The latter finally decide -- despite manifest evidence provided by two previous films that it would be a very bad idea -- to release Loki from jail so that he can fight on their side. Once Loki is back in play, magisterially sneering and loftily dispensing one-liners, the whole thing perks up again. Until, that is, he's off the scene again for reasons which can't be revealed.
The final showdown in Greenwich, London, squares off the Dark Elves and their unleashed Aether against the Asgardians and humans, managing in the process to grind most of Sir Christopher Wren's exquisite 17th century Royal Naval College buildings into a fine, powdery digitally rendered pixel dust. It's here, in this stretch, that the film finally gets its mojo back, finding the requisite balance between bombast and wise-cracks that made the first Thor work in its finest moments. Admittedly, nothing Loki-unrelated in Thor: The Dark World quite matches the hilarity of the scene in the first film where Thor strides into a pet shop and demands a horse, but the finale pleasingly gives the hardworking supports a chance to josh around, the stereoscopy comes into its own, and the editing, credited to Dan Lebental and Wyatt Smith, finds its groove. What a shame the script up until this point is too often so ramshackle and plodding, like the writers were finishing off the dialogue in between catering breaks.
With a project so firmly supervised by its studio, it's hard to tell how much director Alan Taylor should be credited or blamed for the finished result. The Dark World is certainly a far cry from the jaunty little indie crime caper Palookaville (1995) he started his career with. Since then, he's directed some great episodes on some of the very best TV series, including The Sopranos, Mad Men, and, most germane of all in this context, Game of Thrones, on which he also serves as a co-executive producer. Perhaps it's unfair to compare Thrones with The Dark World given the former has so much more scope to build its world over hours of programming, but for all the budget spent on lavish visual effects in The Dark World nothing in it quite compares to the White Walkers marching relentlessly through the snowy Northern wastes at the end of the Taylor-directed episode "Valar Morghulis."
Viewers are advised to not make for the exit as soon as the end credits start rolling and stick it out until the very end if they want to see a postscript that reveals a character who may prove central to the next film. Indeed, the end credits have two Easter-egg scenes, in keeping with the trickle of in-jokes aimed at Marvel aficionados that provides a flash-quick cameo for one of Thor's superhero companions from The Avengers.
Production: Marvel Studios Cast: Chris Hemsworth, Natalie Portman, Tom Hiddleston, Stellan Skarsgard, Idris Elba, Christopher Eccleston, Anthony Hopkins, Rene Russo, Kat Dennings Director: Alan Taylor Screenwriter: Christopher L. Yost, Christopher Markus & Stephen McFeely, based on a story by Don Payne and Robert Rodat Producers: Kevin Feige Executive producers: Nigel Gostelow, Stan Lee, Victoria Alonso, Craig Kyle, Alan Fine, Louis D'Esposito Director of photography: Kramer Morgenthau Production designer: Charles Wood Costume designer: Wendy Partridge Editors: Dan Lebental, Wyatt Smith Music: Brian Taylor
Sequential GO and chemotherapy no benefit for older AML patients according to EORTC/GIMEMA trial
Sequential GO and chemotherapy no benefit for older AML patients according to EORTC/GIMEMA trial
PUBLIC RELEASE DATE:
22-Oct-2013
[
| E-mail
]
Share
Contact: John Bean john.bean@eortc.be European Organisation for Research and Treatment of Cancer
Results of the randomized, phase III, EORTC/GIMEMA 06012 intergroup trial (AML-17) reported in the Journal of Clinical Oncology show that sequential combination of gemtuzumab ozogamicin (GO) and standard chemotherapy provides no benefit for older patients with acute myeloid leukemia (AML) and is too toxic for patients 70 years of age or more. GO is an antibody-drug conjugate comprised of an anti-CD33 monoclonal antibody linked to a cytotoxic agent.
Patients younger than 70 years with secondary acute myeloid leukemia might possibly benefit from such treatment. However, outcomes were significantly worse in the oldest age subgroup due to a higher risk of early mortality.
Prof. Sergio Amadori of the Tor Vergata University Hospital in Rome and Coordinator of this study says, "This large trial in older patients with AML is the third randomized study to assess the addition of GO to chemotherapy in elderly patients with AML. So, it is an important addition to the literature.
Unlike the two trials published so far (French ALFA-0701, and UK NCRI AML16), a higher dose of GO was used, and the GO in induction was given before standard induction chemotherapy. This turns out to be an important difference. While, as shown by the former trials, the addition of low doses of GO to chemotherapy resulted in a survival benefit for older patients with better-risk disease, our study clearly indicates that an intensification strategy combining two upfront higher doses of GO with sequential induction chemotherapy is highly myelosuppressive and not beneficial in older patients, particularly in the oldest age cohort where induction response and survival rates are significantly compromised due to excess early mortality. On the basis of the available studies, there is plausible evidence that lower doses of GO as an adjunct to standard chemotherapy may offer better outcomes for these patients with limited alternatives."
The EORTC GIMEMA trial included 472 patients with newly diagnosed acute myeloid leukemia who were between the ages of 61 and 75 years. Patients were randomly assigned to gemtuzumab ozogamicin (GO), 236 patients, or No GO, 236 patients, arms. The GO arm received a course of gemtuzumab ozogamicin followed by induction chemotherapy with mitoxantrone/cytarabine/etoposide. The No GO arm received only induction chemotherapy. Patients in remission received two consolidation courses with or without gemtuzumab ozogamicin.
Overall response rate was comparable in the two arms: 45% in the GO arm and 49% in the No GO arm. At a median follow-up of 5.2 years, the median overall survival, the primary endpoint, was 7.1 months in the GO arm and 10 months in the No GO arm (hazard ratio [HR], 1.20; 95% CI, 0.99 to 1.45; P = 0.07). Other survival endpoints were similar in both arms. Grade 3/4 hematologic and liver toxicity were greater in the GO arm.
###
The Intergroup EORTC/GIMEMA 06012 trial was coordinated by the EORTC Leukemia Group in collaboration with the GIMEMA Acute Leukemia Working Party and was conducted in 59 sites located in seven countries: Belgium, Croatia, France, Germany, Italy, Portugal, and The Netherlands. This trial was supported by an educational grant from Pfizer.
[
| E-mail
Share
]
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.
Sequential GO and chemotherapy no benefit for older AML patients according to EORTC/GIMEMA trial
PUBLIC RELEASE DATE:
22-Oct-2013
[
| E-mail
]
Share
Contact: John Bean john.bean@eortc.be European Organisation for Research and Treatment of Cancer
Results of the randomized, phase III, EORTC/GIMEMA 06012 intergroup trial (AML-17) reported in the Journal of Clinical Oncology show that sequential combination of gemtuzumab ozogamicin (GO) and standard chemotherapy provides no benefit for older patients with acute myeloid leukemia (AML) and is too toxic for patients 70 years of age or more. GO is an antibody-drug conjugate comprised of an anti-CD33 monoclonal antibody linked to a cytotoxic agent.
Patients younger than 70 years with secondary acute myeloid leukemia might possibly benefit from such treatment. However, outcomes were significantly worse in the oldest age subgroup due to a higher risk of early mortality.
Prof. Sergio Amadori of the Tor Vergata University Hospital in Rome and Coordinator of this study says, "This large trial in older patients with AML is the third randomized study to assess the addition of GO to chemotherapy in elderly patients with AML. So, it is an important addition to the literature.
Unlike the two trials published so far (French ALFA-0701, and UK NCRI AML16), a higher dose of GO was used, and the GO in induction was given before standard induction chemotherapy. This turns out to be an important difference. While, as shown by the former trials, the addition of low doses of GO to chemotherapy resulted in a survival benefit for older patients with better-risk disease, our study clearly indicates that an intensification strategy combining two upfront higher doses of GO with sequential induction chemotherapy is highly myelosuppressive and not beneficial in older patients, particularly in the oldest age cohort where induction response and survival rates are significantly compromised due to excess early mortality. On the basis of the available studies, there is plausible evidence that lower doses of GO as an adjunct to standard chemotherapy may offer better outcomes for these patients with limited alternatives."
The EORTC GIMEMA trial included 472 patients with newly diagnosed acute myeloid leukemia who were between the ages of 61 and 75 years. Patients were randomly assigned to gemtuzumab ozogamicin (GO), 236 patients, or No GO, 236 patients, arms. The GO arm received a course of gemtuzumab ozogamicin followed by induction chemotherapy with mitoxantrone/cytarabine/etoposide. The No GO arm received only induction chemotherapy. Patients in remission received two consolidation courses with or without gemtuzumab ozogamicin.
Overall response rate was comparable in the two arms: 45% in the GO arm and 49% in the No GO arm. At a median follow-up of 5.2 years, the median overall survival, the primary endpoint, was 7.1 months in the GO arm and 10 months in the No GO arm (hazard ratio [HR], 1.20; 95% CI, 0.99 to 1.45; P = 0.07). Other survival endpoints were similar in both arms. Grade 3/4 hematologic and liver toxicity were greater in the GO arm.
###
The Intergroup EORTC/GIMEMA 06012 trial was coordinated by the EORTC Leukemia Group in collaboration with the GIMEMA Acute Leukemia Working Party and was conducted in 59 sites located in seven countries: Belgium, Croatia, France, Germany, Italy, Portugal, and The Netherlands. This trial was supported by an educational grant from Pfizer.
[
| E-mail
Share
]
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.
Get caught up on the day's Nokia news at Windows Phone Central
Nokia debuts a 6-inch Windows Phone with 20MP camera, along with its first Windows RT tablet
This morning at Nokia World in Abu Dhabi, UAE, the Finnish manufacturer has taken the wraps off some of its biggest Windows and Windows Phone devices yet. At the high end there's the Lumia 1520, a 6-inch Windows Phone 8 device with a 1080p display, Snapdragon 800 CPU and a 20-megapixel PureView camera. There's also the mid-range Lumia 1320, which aims to provide a big-screen experience at a more affordable $350 price point. And finally Nokia's Lumia 2520 is the company's first Windows RT tablet, with a 10.1-inch 1080p display inside a thin, colorful chassis.
The Windows Phone Central team are live on the ground in Abu Dhabi, and they've got extensive hands-on coverage of all Nokia's new toys. So hit up the links below to learn more about all the latest devices. And we're far from done with major mobile tech announcements for the day — multi-platform readers will want to check our sibling site iMore later today for full coverage of Apple's iPad announcements from San Francisco.
Our Apple TV has just alerted us to the fact that we'll be able to watch a livestream of Cupertino's big launch show at 10am Pacific Time (1pm ET, 6pm UK) today. Others are seeing it on their black boxes too, according to Macrumors, but it's still not clear whether the event will be streamed to ...
Source: 
![[ Back to EurekAlert! ]](http://www.eurekalert.org/images/back2e.gif){kind=small}
Share
Our Apple TV has just alerted us to the fact that we'll be able to watch a livestream of Cupertino's big launch show at 10am Pacific Time (1pm ET, 6pm UK) today. Others are seeing it on their black boxes too, according to Macrumors, but it's still not clear whether the event will be streamed to ...